March 25, 2020 / 5:40 PM / 9 days ago

BRIEF-Gilead requests FDA pull orphan drug designation from potential coronavirus drug

March 25 (Reuters) - Gilead Sciences Inc:

* Says requested the U.S. FDA rescind the orphan drug designation it was granted for potential coronavirus drug remdesivir

* Says waiving all benefits that accompany orphan drug designation for remdesivir

* Says confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir Further company coverage: (Reporting By Michael Erman)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below